Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333036 | 0.83 | CYP2D6 (0.36) | S1PR3CYP2D6HRH1NFE2L2S1PR1 | |
| SCHEMBL1690313 | 0.80 | CYP2D6 (0.40) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL21071356 | 0.76 | CYP2D6 (0.45) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL30824549 | 0.76 | CYP2D6 (0.45) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL22495173 | 0.76 | CYP2D6 (0.45) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL27147342 | 0.76 | CYP2D6 (0.45) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL28205012 | 0.76 | CYP2D6 (0.39) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL23006304 | 0.75 | CYP2D6 (0.41) | S1PR3CYP2D6HRH1S1PR1DPP4 | |
| SCHEMBL1514943 | 0.75 | S1PR3 (0.38) | S1PR3CYP2D6HRH1S1PR1MEN1 | |
| Hydrochloric Acid SCHEMBL31482194 | 0.75 | LMNA (0.47) | S1PR3CYP2D6HRH1S1PR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930620-A | Tetrafused ring compound, preparation method, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-8338603-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120108642-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2012-05-03 | — | — | US | disclosed |
| US-8084616-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| CN-101835751-A | Cyclohexene amide derivatives and their use as TRPV1 antagonists | ABBOTT LAB | 2010-09-15 | — | — | CN | disclosed |
| EP-2215061-A2 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055629-A2 | CYCLOHEXENEAMIDE DERIVATIVES AND THEIR USE AS TRPV1 ANTAGONIST | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108642-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | S1PR3 269/4885CYP2D6 1965/4885HRH1 63/4885 |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | S1PR3 269/4885CYP2D6 1965/4885HRH1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.